Abstract:BACKGROUND: A growing number of studies suggest that lentinan combined with cisplatin thoracic injection for the treatment of lung cancer is an effective combination of traditional Chinese and Western medicine, which has a continuous and beneficial effect on eliminating clinical symptoms and improving cachexia in lung cancer patients. However, whether this treatment is effective and safe for lung cancer patients or not, evidence supporting the effectiveness and safety of this treatment is still incomplete. Besides, there is lack of systematic review to assess the detailed situation (including risk of bias and methodology) of current related clinical studies.OBJECTIVE: This study aimed to evaluate the effectiveness and safety of lentinan combined with cisplatin thoracic injection in the treatment of lung cancer.METHODS: The major databases (Embase, PubMed, the Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journals Database [VIP] Database, Chinese Biomedical Literature Service System [SinoMed], and Wanfang Database) were searched from inception to March 1, 2020. Randomized controlled trials (RCTs) of lentinan combined with cisplatin chest injection on patients with non-small cell lung cancer (NSCLC) were identified. Two assessors reviewed each trial independently. The methodological quality of the eligible studies was evaluated according to the Cochrane Collaboration's tool for assessing risk of bias. Both the data extraction and the literature quality screening evaluation were conducted independently by 2 researchers.RESULTS: Totally 17 clinical RCTs were included in this study, involving 1390 patients. Meta-analysis results showed that the clinical efficacy (risk ratio [RR] = 1.34, 95% confidence interval [CI] 1.21-1.48), effective subgroup analysis (RR = 1.51, 95% CI 1.3-1.77), and quality of life (RR = 1.48, 95% CI 1.27-1.72), the differences are statistically significant. In terms of adverse reactions, mainly related to gastrointestinal reactions and bone marrow suppression, the incidence and degree of adverse reactions of lentinan combined with cisplatin thoracic injection group were lower than those of cisplatin thoracic injection group alone.CONCLUSIONS: The current evidence prompted that Lentinan combined with cisplatin in thoracic injection might benefit patients with NSCLC on a certain extent; this systematic review revealed some definite conclusions about the application of Lentinan combined with cisplatin in thoracic injection for NSCLC. Due to the low methodological quality, high risk of bias, and inadequate reporting on clinical data, these results still require verification by a large number of well designed, heterogeneous RCT studies. More rigorous, multicenter, sufficient-sample, and double-blind RCTs are warranted.

Clinical effect of highly agglutinative staphylococcin and lentinan combined with cisplatin in treatment of malignant pleural effusion caused by lung cancer

Clinical effect of highly agglutinative staphylococcin combined with cisplatin in treatment of malignant pleural effusion

Short-term effect of combined therapy with Jinlong Capsule (金龙胶囊) and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression

Analysis of Differences of Fever Caused by Cisplatin Combined with Staphylococcin or Lentinan in Malignant Pleural Effusion

Tunnelled pleural catheter insertions and intrapleural administration of drugs for malignant pleural effusion: a clinical control study

Clinical Observation of Close Thoracic Cavity Drainage and Perfusion of Lentinan Combined with Cisplatin on Treating Lung Cancer with Malignant Pleural Effusion

Clinical Observation on Intrapleural Administration of Cisplatin and IL-2 Combined with Systemic Chemotherapy in the Treatment of Malignant Pleural Effusion of Lung Cancer

Intrathoracic infusion therapy with Lentinan and chemical irritants for malignant pleural effusion: a systematic review and meta-analysis of 65 randomized controlled trials

Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis

Therapeutic Effect and Mechanism of Intrapleural Administration of Cisplatin Bound to Activated Carbon Particles for Treating Malignant Pleural Effusion

Clinical effect of Kanglaite injection combined with intrapleural infusion chemotherapy in the treatment of patients with malignant pleural effusion of advanced non - small cell lung cancer

Effect of the combination of recombinant human endostatin injection and intrapleural hyperthermic perfusion with nadaplatin on treatment efficacy of non-small cell lung cancer complicated with pleural effusion

Lentinan combined with cisplatin for the treatment of non-small cell lung cancer

Short-Term and Long-Term Efficacy of Endostar Combined with Cis-Diaminedichloroplatinum in Treating Malignant Pleural Effusion of Non-Small Cell Lung Cancer

Effect of intrapleural perfusion chemotherapy on malignant pleural effusion in patients with non-small cell lung cancer

Short-Term Effect Of Combined Therapy With Jinlong Capsule ((Sic)) And Transcatheter Arterial Chemoembolization On Patients With Primary Hepatic Carcinoma And Its Influence On Serum Osteopontin Expression

Improved Percutaneous Placement Catheters Drainage of Thoracocentesis Accompanying with Intracavitary Chemotherapy for the Treatment of Malignant Pleural Effusion

Effect Of Thoracic Hyperthermic Perfusion With Recombinant Human Endostatin Plus Nedaplatin In Treating Pleural Effusion In Patients With Advanced Non-Small Cell Lung Cancer

Therapeutic Observation of Endostar Combined with Cisdiammi Dichloride Platinum on Non-Small Cell Lung Cancer with Malignant Pleural Effusion

Safety And Efficacy Of Kanglaite Injection In The Treatment Of Malignant Pleural Effusion: A Meta-Analysis